Avience Biomedicals Limited
NNSE:AVIENCE247.90
INR
-6.05
(-2.38%)
ISIN
INE0V9I01017
Return %
Stock
S&P 500
1Y
- -
14.20
3Y
- -
81.12
5Y
- -
68.34
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Semi-annual Revenue
FRC
•
in mil. unless spec.Semi-annual Earnings Per Share
FRC
•
in mil. unless spec.Semi-annual Dividends Per Share
FRC
•
in mil. unless spec.Company Description
- CEO
- Dharam Deo Choudhary
- Sector
- Health technology
- Industry
- Medical specialties
- Address
- New Delhi India
- IPO Date
- Jun 25, 2026
- Website
- avienbio.com
- Similar Companies
- Business
- Avience Biomedicals Limited is an India-based healthcare and biotechnology company engaged in the research, development, manufacturing, and commercialization of pharmaceutical formulations, diagnostic medical solutions, and life sciences products. The company operates through dedicated business divisions including Pharmaceuticals, In-Vitro Diagnostics, Biotechnology, and Medical Consumables. Its comprehensive product and service offerings encompass finished dosage formulations across therapeutic segments including cardiology, oncology, anti-infectives, gastroenterology, and central nervous system disorders; active pharmaceutical ingredients and specialty intermediates; rapid diagnostic test kits, ELISA assay systems, and molecular diagnostic reagents for clinical pathology; automated biochemical analyzers and point-of-care testing devices; surgical disposables, personal protective gear, and medical consumables; and contract research, development, and manufacturing services for third-party pharmaceutical partners. The company serves hospitals, diagnostic laboratories, research institutions, healthcare clinics, and retail pharmacies across domestic Indian markets as well as international territories throughout Southeast Asia, the Middle East, Africa, and Latin America. In recent developments, Avience Biomedicals has expanded its core manufacturing infrastructure with the commissioning of an upgraded, WHO-GMP compliant production facility to scale up the supply of advanced diagnostic panels; entered into strategic co-marketing and distribution agreements to broaden its geographic footprint across high-growth export markets; launched a proprietary line of automated point-of-care testing systems; and broadened its biotechnology pipeline through increased investments in molecular assay research. Founded in 2008, Avience Biomedicals Limited is headquartered in Mumbai, India, and trades on the National Stock Exchange of India under the ticker symbol AVIENCE.